Patent Armory v. GE HealthCare Technologies: Five Call Routing Patents, Dismissed in 56 Days
Patent Armory, Inc. asserted five patents covering intelligent communication routing, telephony control, and auction-based entity matching against GE HealthCare Technologies Inc. in the Northern District of Illinois. The case closed 56 days after filing when Patent Armory voluntarily dismissed without prejudice before GE HealthCare filed any responsive pleading.
Five-Patent Routing Assertion Ends Before GE HealthCare Responds
On 12 February 2025, Patent Armory, Inc. filed suit against GE HealthCare Technologies Inc. in the U.S. District Court for the Northern District of Illinois, asserting infringement of five U.S. patents: US9456086B1, US10491748B1, US7269253B1, US7023979B1, and US10237420B1. The patents collectively cover intelligent communication routing systems, telephony control with intelligent call routing, and methods for matching entities in auction-style frameworks — technologies with broad applicability across enterprise communications and healthcare contact-centre infrastructure.
The case terminated on 9 April 2025 when Patent Armory filed a notice of voluntary dismissal under Federal Rule of Civil Procedure 41(a)(1)(A)(i), dismissing the action without prejudice. Because GE HealthCare had not yet answered the complaint or moved for summary judgment at the time of dismissal, Patent Armory was entitled to dismiss as of right — no court order was required. A without-prejudice dismissal preserves the plaintiff’s right to re-file the same claims, subject to applicable statutes of limitations and any procedural constraints.
A 56-day lifespan before any defendant response suggests the dismissal may reflect early-stage settlement negotiations, a strategic reassessment of claim scope, or a decision to pursue alternative venues or proceedings — though the public record is silent on the underlying driver. The without-prejudice designation means GE HealthCare has obtained no final resolution on the merits, and the asserted patents remain live enforcement tools. Patent Armory, represented by Rabicoff Law LLC — a firm associated with NPE assertion campaigns — may revisit these patents against GE HealthCare or other defendants.
Filing to Voluntary dismissal in 56 days
56 days — resolved before any defendant response was filed
Voluntarily dismissed: what the without-prejudice exit means for both parties
Rule 41(a)(1)(A)(i): dismissal as of right, no court order needed
Under FRCP 41(a)(1)(A)(i), a plaintiff may dismiss an action without a court order at any time before the defendant serves an answer or a motion for summary judgment. Patent Armory filed this notice before GE HealthCare made any such filing, making the dismissal automatic and effective upon filing. This is the lowest-cost exit mechanism available in U.S. federal litigation.
Procedural exit — no merits rulingThe public record does not specify settlement — prejudice status matters
A voluntary dismissal can be with or without prejudice. Without prejudice — the status here — means Patent Armory retains the right to re-file the same claims against GE HealthCare in future, subject to statutes of limitations. With prejudice would bar re-filing. The public record is silent on whether any side agreement, licence, or payment accompanied the dismissal; the court filing alone does not reveal the commercial reality behind the exit.
Re-filing risk remains openPatent Armory exits with all five patents intact and enforceable
Because the dismissal is without prejudice and no invalidity or non-infringement ruling was entered, all five asserted patents remain presumptively valid and enforceable. Patent Armory can assert them again — against GE HealthCare or other targets — without any estoppel from this proceeding. The early exit preserves maximum optionality for future enforcement campaigns.
Patents remain live enforcement toolsGE HealthCare avoids a merits fight — but gains no permanent shield
GE HealthCare escaped this action without substantive litigation cost — no answer, no discovery, no summary judgment motion. However, it obtained no invalidity finding, no licence covenant, and no covenant not to sue on the public record. Absent a confidential side agreement, GE HealthCare remains exposed to re-assertion of all five patents by Patent Armory or any successor in interest.
No permanent protection securedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Patent Armory, Inc. | Company | Non-practising entity — holder of US9456086B1 and four further call routing patentsSearch in Eureka ↗ |
| Defendant | GE HealthCare Technologies Inc. | Company | GE HealthCare Technologies Inc. — global medical technology and healthcare IT companySearch in Eureka ↗ |
| Plaintiff counsel | Isaac Philip Rabicoff | Attorney | Counsel for Patent Armory, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Rabicoff Law LLC | Law Firm | Representing Patent Armory, Inc.Search in Eureka ↗ |
| Presiding judge | Judge Andrea R. Wood | Judge | Illinois Northern District CourtSearch in Eureka ↗ |
Official order — verbatim text
The dismissal notice invokes FRCP 41(a)(1)(A)(i) expressly, confirming that GE HealthCare had filed neither an answer nor a summary judgment motion — making Patent Armory’s right to dismiss unilateral and unconditional. The without-prejudice designation is the operative commercial detail: no claim has been adjudicated, no estoppel created, and no patent invalidated. The phrasing leaves the enforcement posture of all five patents entirely unchanged, and the absence of any court-imposed condition on the dismissal means the parties’ commercial arrangements, if any, remain entirely outside the public record.
US9456086B1 and four further patents — intelligent call routing and telephony control
The five asserted patents span two generations of communication-routing technology. US9456086B1 (application US12/719827) and US10237420B1 (US15/856729) cover intelligent communication routing systems and methods — claim families directed at dynamically directing calls or data communications based on real-time parameters. US10491748B1 (US15/797070) addresses auction-based entity matching, a framework in which routing decisions are made through competitive bidding logic. US7269253B1 (US11/387305) and US7023979B1 (US10/385389) are earlier-generation telephony control patents with intelligent call routing architectures, suggesting a portfolio assembled across multiple filing epochs to capture evolving implementations of the same core routing concept.
The strategic value of this portfolio lies in its breadth across implementation layers: from low-level telephony switching logic in the older patents to higher-level auction and matching algorithms in the newer grants. For healthcare technology companies like GE HealthCare — whose platforms increasingly integrate patient communication, scheduling, and contact-centre capabilities — these claims could be read to cover automated inbound routing, virtual-assistant handoff logic, and AI-assisted triage workflows. The portfolio’s age diversity also complicates invalidity arguments, since prior art searches must be calibrated to multiple priority dates. Any company deploying cloud-based or AI-enhanced communication routing in a regulated healthcare environment should conduct claim-by-claim FTO analysis against this portfolio.
Should your team run an FTO against US9456086B1 and the Patent Armory call routing portfolio?
If your organisation develops or deploys intelligent call routing, virtual telephony switching, contact-centre orchestration, or auction-based lead-routing systems — particularly in healthcare, insurance, or enterprise SaaS — this five-patent portfolio warrants a formal freedom-to-operate review. The without-prejudice dismissal against GE HealthCare confirms Patent Armory is actively asserting these patents in litigation. A targeted FTO analysis should map claim elements of each patent against your specific product architecture, prioritising the newer continuations (US9456086, US10491748, US10237420) which reflect more recent claim drafting.
PatSnap Eureka’s FTO Search Agent can cross-reference all five patent numbers simultaneously, surface the full claim trees and continuation chains, identify cited prior art that may support invalidity arguments, and flag prosecution history estoppel that could limit claim scope. For in-house IP teams monitoring NPE activity in the communications or healthcare IT space, Eureka’s portfolio-watch feature can alert you when Patent Armory — or any assignee of these patents — files new cases, petitions, or continuations, giving your team early warning before a demand letter is served.
Run a freedom-to-operate analysis on US9456086B1 to assess your product’s exposure
Run FTO in Eureka →Similar call routing and telephony patent cases in U.S. district courts
Explore comparable NPE assertion cases involving intelligent call routing and telephony control patents filed in U.S. district courts, including the Northern District of Illinois.
What this case signals for the healthcare communications IP landscape
A five-patent NPE assertion against a major healthcare technology company, closed before any defence was mounted, raises questions every IP team in this sector should be asking.
Early voluntary dismissals often precede re-assertion — monitor Patent Armory
Without-prejudice exits by NPEs frequently signal ongoing licensing negotiations or a pivot to new targets. Companies operating intelligent call routing or contact-centre infrastructure in healthcare should track Patent Armory’s filing activity across all five asserted patents — US9456086, US10491748, US7269253, US7023979, and US10237420.
Telephony and call routing patents carry broad cross-sector reach
The asserted claims cover intelligent routing logic and auction-based matching methods that extend well beyond traditional telecoms. Healthcare IT platforms, patient-engagement systems, and AI-driven communication tools may fall within claim scope. Any enterprise deploying automated call routing should assess exposure before a demand letter arrives.
Patent v GE — key questions answered
Patent Armory, Inc. filed a patent infringement action against GE HealthCare Technologies Inc. on 12 February 2025 in the Northern District of Illinois, asserting five patents covering intelligent call routing and telephony control. On 9 April 2025 — 56 days after filing — Patent Armory voluntarily dismissed the case without prejudice under FRCP 41(a)(1)(A)(i), before GE HealthCare filed any answer or dispositive motion. No merits ruling was entered.
Patent Armory asserted five U.S. patents: US9456086B1 (intelligent communication routing), US10491748B1 (entity matching in an auction), US7269253B1 (telephony control with intelligent call routing), US7023979B1 (telephony control system), and US10237420B1 (intelligent communication routing). The products identified include intelligent communication routing systems and telephony control systems.
A voluntary dismissal without prejudice under FRCP 41(a)(1)(A)(i) means no merits ruling was entered and no claim was adjudicated. All five asserted patents remain presumptively valid and enforceable. Patent Armory retains the right to re-file infringement claims based on these patents against GE HealthCare or any other defendant, subject to applicable statutes of limitations. GE HealthCare gains no estoppel, invalidity finding, or covenant not to sue from this proceeding.
Under FRCP 41(a)(1)(A)(i), a plaintiff may voluntarily dismiss an action without a court order at any time before the opposing party serves an answer or a motion for summary judgment. The case record confirms GE HealthCare had not yet answered the complaint or filed any such motion at the time of dismissal on 9 April 2025, making Patent Armory’s unilateral dismissal procedurally valid without judicial approval.
Not on the basis of this court record alone. The without-prejudice dismissal provides no formal protection — no licence, no covenant not to sue, and no invalidity ruling appears in the public filing. If a confidential settlement or licence was reached, it is not reflected in court documents. Absent such an agreement, GE HealthCare remains exposed to future assertion of all five patents by Patent Armory or any subsequent assignee. Companies in similar positions should consider seeking an express covenant not to sue as a condition of any resolution.
PatSnap Eureka searches patents and litigation data to answer instantly.